← Back to Search

Other

RGT001-075 for Obesity

Phase 2
Waitlist Available
Research Sponsored by Regor Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 weeks
Awards & highlights

Summary

This trial is testing a new medication called RGT001-075 to help overweight individuals lose weight. Participants will be randomly assigned to receive either RGT001-075 or a placebo for 12 weeks

Who is the study for?
This trial is for adults aged 18 to 75 with obesity, defined as having a BMI between 27 and 45. Participants should have maintained a stable body weight for the last three months before starting the trial.Check my eligibility
What is being tested?
The study tests RGT001-075 against a placebo to see if it helps with weight loss. Participants will be randomly assigned to receive either RGT001-075 or a dummy pill daily for 12 weeks.See study design
What are the potential side effects?
Potential side effects of RGT001-075 are not specified here, but common weight loss drug side effects may include nausea, constipation, headache, dry mouth, and dizziness.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with Treatment-emergent Adverse Event(AE) by severity/Serious Adverse Event (SAE), with Clinical Laboratory Abnormalities, Clinically Significant Change From Baseline in Vital Signs and Abnormal Electrocardiogram(ECG) readings
Secondary outcome measures
Change in Body mass index (BMI) in kg/m^2
Change in body weight in kilogram
Change in waist circumference in centimetre
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: RGT001-075 GroupExperimental Treatment1 Intervention
Patients will receive once daily dose of study drug for a total of 12 weeks
Group II: Placebo GroupPlacebo Group1 Intervention
Patients will receive once daily dose of matching placebo for a total of 12 weeks

Find a Location

Who is running the clinical trial?

Regor Pharmaceuticals Inc.Lead Sponsor
4 Previous Clinical Trials
131 Total Patients Enrolled
~49 spots leftby Jul 2025